Answers are grounded in this paper and cite their sources.
Meeting abstracts Anti-CD19 chimeric antigen receptor T cells (CART19) and bi-specific anti-CD19/CD3 antibodies (blinatumomab) are generating unprecedented complete responses in relapsing/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). However, a subset of patients still relapse and
No takes yet. Share an insight, caveat, or question.
Ruella et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: